The conversation discusses Breezula, a hair loss treatment, and its Phase3clinical trial recruitment at 50 locations. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
A phase3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The conversation discusses the effectiveness of RU58841 for hair loss compared to pyrilutamide, which failed to show significant hair regrowth in trials. Some users report personal side effects with RU58841 and question the criteria for success in hair loss treatments.
The conversation is about the release of a new phase3clinical trial for a year and questioning if the results of the 6-month clinicaltrials will be shown this quarter. The specific treatment discussed is Pyrilutamide.